Savara Inc SVRA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
4.72quote price arrow down-0.11 (-2.28%)
Volume
443,231
52 week range
2.16 - 5.70
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.72
  • 52 Week High5.70
  • 52 Week High Date03/05/24
  • 52 Week Low2.16
  • 52 Week Low Date05/17/23

Key Stats

  • Market Cap652.194M
  • Shares Out138.18M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.73
  • YTD % Change0.43

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.72
  • 52 Week High5.70
  • 52 Week High Date03/05/24
  • 52 Week Low2.16
  • 52 Week Low Date05/17/23
  • Market Cap652.194M
  • Shares Out138.18M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.73
  • YTD % Change0.43

RATIOS/PROFITABILITY

  • EPS (TTM)-0.38
  • P/E (TTM)-12.27
  • Fwd P/E (NTM)-11.54
  • EBITDA (TTM)-70.268M
  • ROE (TTM)-58.59%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-4,544,500.00%
  • Debt To Equity (MRQ)21.68%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Savara Inc

 

Profile

MORE
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of...
Matthew Pauls J.D.
Chairman of the Board, Chief Executive Officer
Robert Lutz
Chief Operating Officer
David Lowrance CPA
Chief Financial & Administrative Officer, Secretary
Address
6836 BEE CAVE ROAD
BUILDING 3, SUITE 201
Austin, TX
78746
United States

Top Peers

SYMBOLLASTCHG%CHG
ITOS
Iteos Therapeutics Inc
17.90-0.06-0.33%
LXRX
Lexicon Pharmaceuticals Inc
1.84-0.10-5.15%
LYEL
Lyell Immunopharma Inc
2.78+0.17+6.51%
GHRS
GH Research PLC
12.73-0.01-0.08%
MLYS
Mineralys Therapeutics Inc
13.15+0.08+0.61%